Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

How Is Accelerated or Blast-Phase Myelofibrosis Diagnosed?

At a Glance

Accelerated myelofibrosis is diagnosed when immature blood cells called blasts make up 10% to 19% of the blood or bone marrow; blast phase is 20% or more. Doctors confirm the percentage with blood-smear and bone-marrow testing and investigate other causes of changing counts.

In this answer

3 sections

01

Warning Signs That Prompt Testing

02

Ruling Out Other Causes

03

How Your Doctor Investigates

Accelerated or blast-phase myelofibrosis is diagnosed primarily by the proportion of blasts—very immature blood-forming cells—in your blood or bone marrow [1][2]. When myelofibrosis progresses, these immature cells fail to mature normally and accumulate, causing the proportion of blasts to rise.

Your hematologist will diagnose the accelerated phase if blasts make up 10% to 19% of the cells in your blood or bone marrow [3][1]. The blast phase is diagnosed when blasts reach 20% or higher [2][1]. Blast phase is an aggressive, acute-leukemia-like transformation of myelofibrosis (often called post-myeloproliferative-neoplasm acute myeloid leukemia, or secondary AML) [4][5].

Warning Signs That Prompt Testing

Because these phases are defined by specific laboratory thresholds, doctors rely on changes in your symptoms and routine blood work to know when to investigate further. Note: Laboratory results can fluctuate, and blast percentages below 10% mean the disease is still in the chronic phase. Do not try to self-diagnose from a single report.

  • Changing Blood Counts: A sudden or steady drop in red blood cells (anemia) or platelets, or an unusual spike in white blood cells, can be a warning sign [6][7]. An increase in the number of blasts seen in routine blood tests can also raise concern. For instance, while a blast count of 3% to 9% does not mean you are in accelerated phase, it is a risk signal that will prompt your doctor to monitor you more closely [6][8].
  • Worsening Symptoms: A return or worsening of “constitutional symptoms” (severe fatigue, drenching night sweats, fevers, or unintended weight loss) [9][10].
  • Spleen Changes: A spleen that rapidly becomes larger or more uncomfortable [9].
  • New Complications: Unexplained bleeding or unusual, frequent infections [11][10].

When to Seek Urgent Help: Contact your hematology team promptly if you develop a new fever or new bleeding. Seek emergency care for uncontrolled bleeding, severe shortness of breath, chest pain, confusion, or other severe symptoms. Do not stop or change medications like ruxolitinib without medical advice, as abrupt changes can cause complications.

Ruling Out Other Causes

Worsening blood counts or symptoms do not automatically mean your myelofibrosis is accelerating. While a confirmed high blast count (10% or more) defines progression, your care team will also urgently investigate alternative causes for your symptoms and changing counts [12][11]:

  • Medication Effects: Treatments for myelofibrosis, particularly JAK inhibitors like ruxolitinib, can slow the bone marrow’s production of blood cells (a side effect called myelosuppression) [12][13].
  • Infections: People with myelofibrosis have a higher risk of infections, which can temporarily disrupt blood counts and cause fevers or fatigue [14][15].
  • Bleeding: A drop in red blood cells might be caused by an undiagnosed bleeding issue [11].

How Your Doctor Investigates

If your doctor suspects progression, they will order a comprehensive evaluation [16][17]. The diagnosis is based on the exact blast count in the context of your overall marrow health, not just a single genetic test or symptom.

  • Blood Tests and Smear Review: A routine complete blood count (CBC) with a manual “smear” review (looking at blood cells under a microscope) can help establish the blast percentage in your circulating blood [3][16].
  • Bone Marrow Evaluation: A bone marrow biopsy involves taking a small sample of liquid (aspirate) and solid bone (core biopsy) from your hip bone. Because myelofibrosis causes severe scarring, the liquid aspirate can be difficult to obtain, so doctors use the core biopsy and other tests to carefully examine the cells [18][17]. Flow cytometry may also be used to identify specific types of cells.
  • Cytogenetic (Chromosome) Testing: This looks at the large structures of DNA in your cells for high-risk chromosomal changes [3][19].
  • Molecular (Gene) Testing: This looks for specific genetic mutations (like TP53 or IDH1/2) [3][20].

Important Note: Finding new mutations does not “confirm” accelerated or blast phase on its own, and a person’s disease can progress without acquiring any new mutations. Instead, these genetic results help your doctor estimate your prognosis, distinguish between other conditions, and identify targeted treatment options [19][21].

Common questions in this guide

What blast percentage means that myelofibrosis is accelerated or in blast phase?
Accelerated phase means blasts make up 10% to 19% of the cells in your blood or bone marrow. Blast phase means the percentage is 20% or higher. A result below 10% is not, by itself, accelerated or blast phase, although 3% to 9% can signal higher risk and closer monitoring.
Which tests are used to diagnose progression to blast phase?
Doctors usually review a complete blood count and manual blood smear, then may perform a bone marrow aspirate and core biopsy. Flow cytometry, chromosome testing, and gene testing can add information about the abnormal cells and risk. The diagnosis depends mainly on the blast percentage in blood or bone marrow and the overall marrow findings, not on one test alone.
Can genetic mutations alone confirm accelerated or blast-phase myelofibrosis?
No. New gene changes can help estimate prognosis, distinguish other conditions, or identify targeted treatment options, but they do not establish the phase by themselves. Myelofibrosis can progress without acquiring new mutations.
Could an infection or myelofibrosis medication explain my changing blood counts?
Yes. Infections, bleeding, and medicines such as the JAK inhibitor ruxolitinib can cause fever, fatigue, anemia, or other changes in blood counts. Your care team will investigate these possibilities rather than assuming that every change means accelerated or blast-phase disease.
When should I contact my doctor about possible progression?
Contact your hematology team promptly for a new fever or new bleeding. Seek emergency care for uncontrolled bleeding, severe shortness of breath, chest pain, confusion, or other severe symptoms. Do not stop or change ruxolitinib or another medication without medical advice.
What happens if scarring makes a bone marrow aspiration difficult?
Myelofibrosis can make it hard to obtain the liquid marrow sample. Doctors can use the core biopsy, blood findings, flow cytometry, and other laboratory tests to assess the cells and blast percentage. Ask your hematology team which combination provides enough information in your case.

Related questions

How Do Doctors Choose a JAK Inhibitor for Myelofibrosis? Can My Myelofibrosis Risk Score Change Over Time? Does Prefibrotic Myelofibrosis Need Treatment or Monitoring? How to Manage Fullness and Weight Loss in Myelofibrosis? How Common Is Myelofibrosis and Who Is at Risk? Explained
Show more
How Are Low Platelets and Bleeding Treated in Myelofibrosis? How Is Myelofibrosis-Related Anemia Treated? Key Options How Is Post-PV/ET Myelofibrosis Different From Primary MF? How Often Are Myelofibrosis Monitoring Visits Needed? Is Myelofibrosis Hereditary? Should Relatives Be Tested? What Are My Treatment Options if a JAK Inhibitor Fails? Positive JAK2, CALR or MPL Post-Transplant: What Now? What Does Triple-Negative Myelofibrosis Mean for Your Care? What Do White Blood Cell Counts Mean in Myelofibrosis? Can I Exercise Safely With Myelofibrosis and Splenomegaly? What Happens During a Bone Marrow Biopsy for Myelofibrosis? What If I Need Frequent Transfusions for Myelofibrosis? What Blood Tests Are Needed for JAK Inhibitors in Myelofibrosis? When Should Myelofibrosis Tests Be Repeated After Changes?

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.

    Tefferi A, Alkhateeb H, Gangat N

    Blood cancer journal 2023; (13(1)):108 doi:10.1038/s41408-023-00878-8.

    PMID: 37460550
  2. 2

    Accelerated and blast phase myeloproliferative neoplasms.

    Saliba AN, Gangat N

    Best practice & research. Clinical haematology 2022; (35(2)):101379 doi:10.1016/j.beha.2022.101379.

    PMID: 36333070
  3. 3

    Accelerated Phase of Myeloproliferative Neoplasms.

    Shahin OA, Chifotides HT, Bose P, et al.

    Acta haematologica 2021; (144(5)):484-499 doi:10.1159/000512929.

    PMID: 33882481
  4. 4

    Management of advanced phase myeloproliferative neoplasms.

    Marcellino B, Mascarenhas J

    Clinical advances in hematology & oncology : H&O 2019; (17(7)):405-411.

    PMID: 31449507
  5. 5

    A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.

    Chen D, Fuda F, Weinberg O

    International journal of laboratory hematology 2021; (43 Suppl 1()):78-81 doi:10.1111/ijlh.13565.

    PMID: 34288445
  6. 6

    MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Guglielmelli P, Lasho TL, Rotunno G, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(4)):310-318 doi:10.1200/JCO.2017.76.4886.

    PMID: 29226763
  7. 7

    Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.

    Masarova L, Bose P, Pemmaraju N, et al.

    Cancer 2020; (126(19)):4322-4331 doi:10.1002/cncr.33094.

    PMID: 32697338
  8. 8

    Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis.

    Gagelmann N, Wolschke C, Salit RB, et al.

    Blood advances 2022; (6(4)):1222-1231 doi:10.1182/bloodadvances.2021006827.

    PMID: 35051996
  9. 9

    High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis.

    Lucijanic M, Livun A, Stoos-Veic T, et al.

    Hematology (Amsterdam, Netherlands) 2018; (23(4)):201-207 doi:10.1080/10245332.2017.1376843.

    PMID: 28906207
  10. 10

    Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

    Griesshammer M, Al-Ali HK, Baerlocher GM, et al.

    International journal of cancer 2026; (159(7)):1642-1662 doi:10.1002/ijc.70596.

    PMID: 42324204
  11. 11

    [Myelofibrosis: A review].

    Genthon A, Killian M, Mertz P, et al.

    La Revue de medecine interne 2021; (42(2)):101-109 doi:10.1016/j.revmed.2020.08.018.

    PMID: 33243417
  12. 12

    SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.

    Hochman MJ, Vale CA, Hunter AM

    Clinical lymphoma, myeloma & leukemia 2025; (25(4)):226-239 doi:10.1016/j.clml.2024.09.001.

    PMID: 39358153
  13. 13

    Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

    Verstovsek S, Mesa RA, Gotlib J, et al.

    Journal of hematology & oncology 2017; (10(1)):55 doi:10.1186/s13045-017-0417-z.

    PMID: 28228106
  14. 14

    Management of Myelofibrosis: from Diagnosis to New Target Therapies.

    Iurlo A, Cattaneo D, Bucelli C

    Current treatment options in oncology 2020; (21(6)):46 doi:10.1007/s11864-020-00734-y.

    PMID: 32350623
  15. 15

    Myelofibrosis: Treatment Options After Ruxolitinib Failure.

    Stuckey R, Segura Díaz A, Gómez-Casares MT

    Current oncology (Toronto, Ont.) 2025; (32(6)) doi:10.3390/curroncol32060339.

    PMID: 40558282
  16. 16

    Myelofibrosis.

    Passamonti F, Mora B

    Blood 2023; (141(16)):1954-1970 doi:10.1182/blood.2022017423.

    PMID: 36416738
  17. 17

    [Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].

    Yuan XG, Wan RT, Zhao XW, et al.

    Zhongguo shi yan xue ye xue za zhi 2021; (29(4)):1236-1241 doi:10.19746/j.cnki.issn.1009-2137.2021.04.033.

    PMID: 34362508
  18. 18

    Bone Marrow Cell Depletion in Myelofibrosis Is Associated With High-Risk Features and Shortened Survival: A Bone Marrow Pathology Group Study.

    Geyer JT, Abu-Zeinah G, Sy C, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2026; 101106 doi:10.1016/j.modpat.2026.101106.

    PMID: 42933695
  19. 19

    Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2023; (98(5)):801-821 doi:10.1002/ajh.26857.

    PMID: 36680511
  20. 20

    Impact of molecular profiling on the management of patients with myelofibrosis.

    Pastor-Galán I, Martín I, Ferrer B, Hernández-Boluda JC

    Cancer treatment reviews 2022; (109()):102435 doi:10.1016/j.ctrv.2022.102435.

    PMID: 35839532
  21. 21

    The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

    McNamara CJ, Panzarella T, Kennedy JA, et al.

    Blood advances 2018; (2(20)):2658-2671 doi:10.1182/bloodadvances.2018021469.

    PMID: 30327374

This page explains how accelerated or blast-phase myelofibrosis is evaluated for educational purposes and does not replace medical advice. Your hematology team should interpret your blood and bone marrow results.